Pancreatic cancer is cancer that forms in the cells of the pancreas. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control. The cancer can be diagnosed with the help of ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Treatment may include surgery, radiation, chemotherapy, or a combination of these.
Market Dynamics:
Rise in incidence and prevalence of pancreatic cancer, rise in development of novel therapeutics, growing geriatric population, increase in demand for safe and effective therapeutics, and increase in awareness among people are major factors expected to augment growth of the global pancreatic cancer therapeutics and diagnostic market.
For instance, in January 2021, Myriad Genetics Inc. and Illumina Inc. collaborated to develop a kit-based version of the myChoice companion diagnostic test for international markets, which can be used to detect pancreatic cancer.
Moreover, in September 2020, the Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research (NICPR) launched www.cancerindia.org with the theme ‘India against Cancer, a portal that provides information on the leading cancers in India with the major focus on awareness, prevention, and treatment of cancers, including pancreatic cancer.
Key features of the study:
- This report provides in-depth analysis of the global pancreatic cancer therapeutics and diagnostic market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global pancreatic cancer therapeutics and diagnostic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include F Hoffmann-La Roche AG, Merck KgaA, Apexigen Inc., Immunovia AB, Viatris Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb, Novartis AG, Pfizer Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, FUJIFILM Holdings Corporation, Boston Scientific Corporation, and Rafael Holdings Inc. (Rafael Pharmaceuticals), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global pancreatic cancer therapeutics and diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pancreatic cancer therapeutics and diagnostic market.
Detailed Segmentation:
- Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type:
- Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Geography:
- North America
- Europe
- Asia Pacific
- Middle East
- Africa
- Latin America
- Company Profiles:
- F.Hoffmann-La Roche AG
- Merck KgaA
- Apexigen Inc.
- Immunovia AB
- Viatris Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb
- Novartis AG
- Pfizer Inc.
- Myriad Genetics Inc.
- Canon Medical Systems Corporation
- FUJIFILM Holdings Corporation
- Boston Scientific Corporation
- Rafael Holdings Inc. (Rafael Pharmaceuticals)
